Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06601296 · ClinicalTrials.gov registry record · Phase 2
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
A Phase 2 study of Metastatic Renal Cell Carcinoma ( mRCC) and OligoProgressive Metastatic Disease, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06601296: Recruiting Phase 2 study of Metastatic Renal Cell Carcinoma ( mRCC) and OligoProgressive Metastatic Disease, sponsored by University of Texas Southwestern Medical Center.
NCT06601296 is a Phase 2 study of Metastatic Renal Cell Carcinoma ( mRCC) and OligoProgressive Metastatic Disease that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06601296, a Phase 2 study of Metastatic Renal Cell Carcinoma ( mRCC) and OligoProgressive Metastatic Disease, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
Primary Outcome
Exact binomial test will be used to test if the lower limit of the 95% confidence interval of the probability of postponing systemic therapy \>9 months will be greater than 30%.
Conditions Studied
Interventions
- DRUG IMSA101
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
What NCT06601296 shows while recruiting
NCT06601296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Metastatic Renal Cell Carcinoma ( mRCC) appearing as the primary indexed condition, and to 1 intervention - of which IMSA101 is the first listed.
NCT06601296 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06601296 about?
NCT06601296 is a clinical study titled "Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer". To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
What is the current status of trial NCT06601296?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-04-01. Estimated completion is 2028-10.
What conditions does trial NCT06601296 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease.
What interventions are being tested in trial NCT06601296?
The interventions under investigation include: IMSA101 (DRUG).
Who is sponsoring clinical trial NCT06601296?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06601296 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma ( mRCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06601296's enrollment target sits among peer trials
15 1920th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI